Sinovac Biotech’s COVID-19 vaccine is unable to produce sufficient antibodies to neutralize the highly mutated Omicron strain of the coronavirus, according to a new study by the University of Hong Kong. The Chinese Sinovac vaccine provides “inadequate” antibodies against the Omicron variant of the coronavirus, according to researchers.
Continue reading now
Get 30 days of free access to the Professional Briefing to read these and more quality news every day.
Are you already a guest at the China.Table? Log in now